Susanne Schaffert, Member of the Supervisory Board of BioNTech SE, shared a post on LinkedIn:
“I am deeply honored and grateful to have been elected to the Supervisory Board of BioNTech SE at the company’s AGM.
BioNTech SE has built an extraordinary oncology pipeline and continues to push the boundaries of what is possible in cancer treatment. With its late-stage candidates and its discovery and early research, I firmly believe the company is uniquely positioned to help shape the future of oncology and bring transformative therapies to patients worldwide.
Throughout my career, one mission has remained constant: improving the lives of cancer patients through innovation, science, and collaboration.
I am excited to contribute my experience, network, and passion to support BioNTech SE on this important journey.
My sincere thanks to Helmut Jeggle, Ugur Sahin and all BioNTech shareholders for their trust and confidence. I look forward to working alongside an exceptional team to help shape the next chapter of this outstanding company and advance the future of cancer care.”
Other articles about BioNTech SE on OncoDaily.